Recommendations of the Italian League Against Epilepsy Working Group on Generic Products of Antiepileptic Drugs

Summary:  The availability of generic products of antiepileptic drugs (AEDs) has been increasing in recent years. In view of the importance of the issue, the Italian League against Epilepsy (LICE) set up an ad hoc working group whose task was to assess available evidence on the efficacy and safety of generic AEDs in the treatment of epilepsy and to produce recommendations on their use. A careful review of the literature revealed no adequately powered randomized controlled trials that assessed the risk/benefit ratio of generic substitution. Although there have been reports of loss or worsened seizure control, or appearance of adverse events, following the switch from brand products to generics, a critical assessment of the evidence generally does not allow us to establish a cause–effect relationship between the switch and a change in clinical status. Overall, the working group concluded that generic AEDs meeting current regulatory criteria for bioequivalence represent a valuable choice in the management of epilepsy by allowing a substantial reduction of treatment costs, particularly in patients initiating monotherapy or adjunctive treament and in those with persistent seizures. The working group considered that in patients who achieved seizure freedom a modest change in plasma drug levels, which may occasionally occur even after substitution of products that meet bioequivalence criteria, could in rare cases lead to seizure breakthrough. Therefore, generic substitution is not recommended in patients who achieved seizure remission. Switches between a particular generic and another generic should also be preferably avoided. Finally, sustained‐release AED formulations should not be used interchangeably with immediate‐release brand or generic products. Patients need to be informed about the stringent criteria that currently govern the approval of generic products and about the implications of the use of generic AEDs, and their opinion should be taken into consideration at the time of prescribing.

[1]  M. Mikati,et al.  Double‐Blind Randomized Study Comparing Brand‐Name and Generic Phenytoin Monotherapy , 1992, Epilepsia.

[2]  E. Wyllie,et al.  Increased seizure frequency with generic primidone. , 1987, JAMA.

[3]  J. Macdonald Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product , 1987, Neurology.

[4]  Vinod P. Shah,et al.  The Bioinequivalence of Carbamazepine Tablets with a History of Clinical Failures , 1992, Pharmaceutical Research.

[5]  R. Sachdeo,et al.  GENERIC VERSUS BRANDED CARBAMAZEPINE , 1987, The Lancet.

[6]  J. L. Herranz,et al.  Impacto clínico y económico de los fármacos genéricos en el tratamiento de la epilepsia , 2005 .

[7]  A. Richens,et al.  Bioavailability and dissolution of proprietary and generic formulations of phenytoin. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[8]  J. Lowe,et al.  Comparison of Steady‐State Blood Levels of Two Carbamazepine Formulations , 1989, Epilepsia.

[9]  V. Preedy,et al.  Scottish Intercollegiate Guidelines Network , 2010 .

[10]  A. Cawood,et al.  BIO‐AVAILABILITY AND DISSOLUTION OF THREE PHENYTOIN PREPARATIONS FOR CHILDREN , 1986, Developmental Medicine & Child Neurology.

[11]  M. Duchowny,et al.  Carbamazepine toxicity resulting from generic substitution , 1993, Neurology.

[12]  T. Suppes,et al.  Gastrointestinal side-effects after switch to generic valproic acid. , 1998, Pharmacopsychiatry.

[13]  O. Pelkonen,et al.  Interindividual variability in human drug metabolism , 2001 .

[14]  K. Kraushaar,et al.  Effects of switching from Depakene to generic valproic acid on individuals with mental retardation. , 1997, Mental retardation.

[15]  R. Hartley,et al.  Breakthrough seizures with generic carbamazepine: a consequence of poorer bioavailability? , 1990, The British journal of clinical practice.

[16]  B. Ballinger,et al.  Bioavailability of phenytoin. A comparison of two preparations , 1975, European Journal of Clinical Pharmacology.

[17]  G. Koch,et al.  Untoward effects of generic carbamazepine therapy. , 1987, Archives of neurology.

[18]  A. Guberman,et al.  Generic Substitution for Brand Name Antiepileptic Drugs: A Survey , 2000, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[19]  G. Krämer,et al.  Risiken der neuen Aut-idem-Regelung für die Behandlung mit Antiepileptika , 2002 .

[20]  P. Tammisto,et al.  BIOAVAILABILTY OF PHENYTOIN , 1976, The Lancet.

[21]  F. Bochner,et al.  Factors involved in an outbreak of phenytoin intoxication. , 1972, Journal of the neurological sciences.

[22]  K. Jain Investigation and Management of Loss of Efficacy of an Antiepileptic Medication Using Carbamazepine as an Example , 1993, Journal of the Royal Society of Medicine.

[23]  J. Takanashi,et al.  Vascular neurology: A new neurologic subspecialty , 2005, Neurology.

[24]  J. G. Dios,et al.  Fármacos genéricos en el tratamiento de la epilepsia , 2005 .

[25]  R. Reading,et al.  Generic prescribing for epilepsy. Is it safe? , 1997, Seizure.

[26]  M. Eichelbaum,et al.  The bioavailability of phenytoin , 1977, Journal of Neurology.

[27]  J. Manson,et al.  Bioavailability of phenytoin from various pharmaceutical preparations in children. , 1975, The Medical journal of Australia.

[28]  Timothy E. Welty,et al.  Loss of Seizure Control Associated with Generic Substitution of Carbamazepine , 1992, The Annals of pharmacotherapy.

[29]  F. Besag Is Generic Prescribing Acceptable in Epilepsy? , 2000, Drug safety.

[30]  G. Mathern,et al.  Epilepsia , 1991, NEURO FUNDAMENTAL.

[31]  W. O'reilly,et al.  Plasma phenytoin levels produced by various phenytoin preparations. , 1975, The Medical journal of Australia.

[32]  K. Tomaszewski,et al.  Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy , 2005, Epilepsy & Behavior.

[33]  I. Leppik,et al.  Compliance and variability of plasma phenytoin levels in epileptic patients , 1979 .

[34]  A. Wilner Therapeutic equivalency of generic antiepileptic drugs: results of a survey , 2004, Epilepsy & Behavior.

[35]  J. French,et al.  Comparative Bioavailability of a Generic Phenytoin and Dilantin , 1994, Epilepsia.

[36]  A. Richens Impact of Generic Substitution of Anticonvulsants on the Treatment of Epilepsy , 1997, CNS drugs.

[37]  Assessment: Generic substitution for antiepileptic medication , 1990 .